PMID- 35050757 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220210 IS - 2473-4284 (Electronic) IS - 2473-4284 (Linking) VI - 4 DP - 2020 Nov TI - Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. PG - 829-840 LID - 10.1200/PO.20.00021 [doi] AB - PURPOSE: Hyperprogressive disease (HPD), fast progression (FP), and early death (ED) have been described in 13.8%, 4.7%, and 5.6% and in 5.1%, 2.8%, and 6.8%, respectively, of patients with non-small-cell lung cancer (NSCLC) treated with single-agent programmed cell death ligand 1 inhibitors (ICI) or chemotherapy, respectively. Whether FP/ED and HPD represent overlapping patterns is unknown. PATIENTS AND METHODS: FP, ED, and HPD were retrospectively assessed in patients with NSCLC treated with single-agent ICI or chemotherapy. Eligibility required 2 computed tomography (CT) scans before and 1 CT scan during treatment. (1) HPD, (2) FP, (3) ED were defined as (1) RECIST version 1.1 progression at first CT scan and tumor growth rate variation per month > 50%, (2) >/= 50% increase in the sum of the longest diameters of target lesions within 6 weeks from baseline, and (3) death as a result of radiologic progression within 12 weeks from baseline CT scan, respectively. RESULTS: Of 406 ICI-treated NSCLC, 56 patients (13.8%), 9 patients (2.2%), and 36 patients (8.8%) were HPD, FP, and ED, respectively. Eight (14.2%) and 20 (35.7%) of 56 patients with HPD were also FP and ED. ED significantly correlated with baseline Eastern Cooperative Oncology Group performance status >/= 2 compared with HPD (33% v 13%, P = .02). Overall survival was significantly longer for HPD (3.4 months [95% CI, 2.7 to 4.0 months]) compared with FP (0.7 months [95% CI, 0.6 to 0.8 months]); HR, 0.18 [95% CI, 0.08 to 0.42]; P < .0001) and ED (1.4 months [95% CI, 1.3 to 1.6 months]); HR, 0.19 [95% CI, 0.11 to 0.34]); P < .0001), whereas it did not differ between FP and ED (HR, 1.3 [95% CI, 0.56 to 3.0]; P = .55). Of 59 patients with NSCLC treated with single-agent chemotherapy, the HPD, FP, and ED rates were 5.1%, 1.7%, and 6.7%, respectively. CONCLUSION: FP, ED, and HPD represent distinct progression patterns with limited overlap and different survival outcomes. FAU - Ferrara, Roberto AU - Ferrara R AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. AD - Medical Oncology Department, Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Mezquita, Laura AU - Mezquita L AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. FAU - Texier, Matthieu AU - Texier M AD - Biostatistics and Epidemiology Department, Gustave Roussy, Villejuif, France. FAU - Lahmar, Jihene AU - Lahmar J AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. FAU - Audigier-Valette, Clarisse AU - Audigier-Valette C AD - Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France. FAU - Tessonnier, Laurent AU - Tessonnier L AD - Nuclear Medicine Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France. FAU - Mazieres, Julien AU - Mazieres J AD - Pneumology Department, Centre Hospitalier Universitaire de Toulouse, Universite Paul Sabatier, Toulouse, France. FAU - Zalcman, Gerard AU - Zalcman G AD - Thoracic Oncology Department, Hopital Bichat-Claude Bernard, Universite Paris-Diderot, Paris, France. FAU - Brosseau, Solenn AU - Brosseau S AD - Thoracic Oncology Department, Hopital Bichat-Claude Bernard, Universite Paris-Diderot, Paris, France. FAU - Le Moulec, Sylvestre AU - Le Moulec S AD - Medical Oncology Department, Institute Bergonie, Bordeaux, France. FAU - Leroy, Laura AU - Leroy L AD - Medical Oncology Department, Institute Bergonie, Bordeaux, France. FAU - Duchemann, Boris AU - Duchemann B AD - Medical Oncology Department, Hopital Avicenne, Bobigny, France. FAU - Lefebvre, Corentin AU - Lefebvre C AD - Service des Maladies Respiratoires, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. FAU - Veillon, Remi AU - Veillon R AD - Service des Maladies Respiratoires, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. FAU - Westeel, Virginie AU - Westeel V AD - Pneumology Department, Centre Hospitalier Universitaire de Besancon, Besancon, France. FAU - Koscielny, Serge AU - Koscielny S AD - Biostatistics and Epidemiology Department, Gustave Roussy, Villejuif, France. FAU - Champiat, Stephane AU - Champiat S AD - Drug Development Department, Gustave Roussy, Villejuif, France. AD - Radiology Department, Gustave Roussy, Villejuif, France. FAU - Ferte, Charles AU - Ferte C AD - Drug Development Department, Gustave Roussy, Villejuif, France. AD - Radiology Department, Gustave Roussy, Villejuif, France. FAU - Planchard, David AU - Planchard D AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. FAU - Remon, Jordi AU - Remon J AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. FAU - Boucher, Marie Eve AU - Boucher ME AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. FAU - Gazzah, Anas AU - Gazzah A AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. FAU - Adam, Julien AU - Adam J AD - Pathology Department, Gustave Roussy, Villejuif, France. FAU - Lo Russo, Giuseppe AU - Lo Russo G AD - Medical Oncology Department, Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Signorelli, Diego AU - Signorelli D AD - Medical Oncology Department, Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Garassino, Marina Chiara AU - Garassino MC AD - Medical Oncology Department, Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Soria, Jean Charles AU - Soria JC AD - University Paris Sud, Orsay, Faculty of Medicine, Paris, France. FAU - Caramella, Caroline AU - Caramella C AD - Radiology Department, Gustave Roussy, Villejuif, France. FAU - Besse, Benjamin AU - Besse B AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. LA - eng PT - Journal Article PL - United States TA - JCO Precis Oncol JT - JCO precision oncology JID - 101705370 SB - IM EDAT- 2020/11/01 00:00 MHDA- 2020/11/01 00:01 CRDT- 2022/01/20 17:38 PHST- 2022/01/20 17:38 [entrez] PHST- 2020/11/01 00:00 [pubmed] PHST- 2020/11/01 00:01 [medline] AID - 10.1200/PO.20.00021 [doi] PST - ppublish SO - JCO Precis Oncol. 2020 Nov;4:829-840. doi: 10.1200/PO.20.00021.